|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:Asia
gptkb:Europe
gptkb:Russia
1978
|
|
gptkbp:ATCCode
|
C01EB15
|
|
gptkbp:bannedIn
|
gptkb:World_Anti-Doping_Agency
athletic competition
|
|
gptkbp:brand
|
Idaptan
Preductal
Vastarel
|
|
gptkbp:CASNumber
|
13171-25-0
|
|
gptkbp:category
|
antianginal agent
piperazine derivative
metabolic modulator
|
|
gptkbp:compatibleWith
|
gptkb:Canada
gptkb:United_States
|
|
gptkbp:contraindication
|
gptkb:Parkinson's_disease
movement disorders
|
|
gptkbp:discoveredBy
|
gptkb:Servier_Laboratories
|
|
gptkbp:eliminationHalfLife
|
6 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C14H22N2O3
|
|
gptkbp:hasSMILES
|
CC1=CC(=CC=C1)CN(CCO)CC(=O)N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Trimetazidine
|
|
gptkbp:IUPACName
|
1-(2,3,4-trimethoxybenzyl)piperazine
|
|
gptkbp:KEGGID
|
D08610
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits fatty acid oxidation
metabolic agent
|
|
gptkbp:molecularWeight
|
266.34 g/mol
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1427
5277
DB09073
5476
|
|
gptkbp:riskFactor
|
may cause movement disorders
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
parkinsonism
gait disorders
restless leg syndrome
|
|
gptkbp:UNII
|
6GQ3D2Q752
|
|
gptkbp:usedFor
|
ischemic heart disease
angina pectoris
|
|
gptkbp:bfsParent
|
gptkb:TMA
gptkb:Servier
gptkb:Servier_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
7
|